CD86 and neoplasm: Flow cytometric analysis demonstrated a dose-dependent increase in the proportion of CD80+ CD86+ double-positive cells among CD11c+ MHC-II+ BMDCs (Fig. 4D), and quantitative analysis confirmed significant enhancement of BMDC maturation following treatment with supernatants from P. aeruginosa-treated tumor cells (Fig. 4E).